News
Start-up secures US$26m to develop technology to reduce preterm births
Novocuff has developed a medical device aimed at extending pregnancy and reducing preterm births

The US medical device company Novocuff has raised US$26m in funding to advance its technology aimed at reducing preterm births.
Preterm premature rupture of membranes and cervical shortening are leading causes of preterm birth, affecting millions of families worldwide each year.
Novocuff aims to address these conditions and improve pregnancy outcomes through what it describes as a “novel” approach.
The company has developed a medical device aimed at stabilising and closing the cervix to retain amniotic fluid and sustain cervical length, with the goal of extending pregnancy.
Series A proceeds are hoped to support Novocuff’s growth plans, including the expansion of its team, execution of a US clinical study, marketing authorisation and early-stage commercialisation.
Amelia Degenkolb, co-founder and CEO of Novocuff, said: “We are thrilled to have the support of a strong and mission-aligned group of investors as we enter this exciting next phase of clinical development.
“This funding catalyses our ability to deliver a solution to a healthcare need for women, and their families and healthcare providers.”
AXA IM Alts, through its Global Healthcare Private Equity Strategy, led the round with a US$14m investment, alongside participation from Laerdal Million Lives Fund, and support from existing investors and new investors Laborie, RH Capital, Avestria Ventures and March of Dimes.
Curt LaBelle, head of healthcare private equity at AXA IM Alts, said: “As the leading cause of infant mortality globally, preterm birth is a serious unaddressed global health issue. The near and long-term negative impacts on the patient, and the economic burden on health systems, have created a pressing and dire situation.
“Given the lack of solutions currently available to address this significant global health challenge, we are thrilled to directly contribute to Novocuff’s mission to improve pregnancy outcomes.
“We have followed Novocuff since its founding and are excited about the company’s progress and clinical data generated to date.
“Our investment should enable completion of a US pivotal trial and the introduction of the Novocuff device to global markets, including low- and middle-income countries.”
He added: “This aligns with our commitment at AXA IM Alts of generating measurable and positive healthcare outcomes alongside attractive long-term financial returns for our investors.”
Becca Shmukler, principal at the Laerdal Million Lives Fund, commented: “Tragically, preterm birth is the number one cause of infant mortality globally.
“When we first met co-founders Amy and Donald and initially invested in the company, we were impressed by their novel technology, expertise, and commitment to addressing this sorely underserved market.
Working with them across the last year has only grown our conviction in Novocuff’s potential to lower the mortality burden associated with preterm birth – perfectly aligned with the Laerdal Million Lives Fund’s life-saving mission.
“With this Series A financing, we are now looking forward to partnering with mission-aligned investors like AXA IM Alts to continue to work toward this goal.”
Eric Schaefer, senior director of portfolio strategy and mission investment at March of Dimes, shared: “Too many babies are born too soon, which is why preventing preterm birth and potentially poor outcomes for mum and baby is critical to March of Dimes.
“The investments we make through our Innovation Fund help to support the development of new solutions such as Novocuff’s device, which we hope will help address pregnancy complications that can lead to preterm birth. We are encouraged by Novocuff’s progress to date and look forward to the results from their upcoming clinical trial.”
To receive the Femtech World newsletter, sign up here.
Fertility
GLP-1 drugs do not increase pregnancy risks, study finds
Cancer
New scan could speed up endometriosis diagnosis

Obesity may be a key driver of rising rates of 11 cancers in adults under 50, a study has found.
The 11 cancers were thyroid, multiple myeloma, liver, kidney, gallbladder, colorectal, pancreatic, endometrial, oral, breast and ovarian cancers.
All except oral cancer are known to be linked to excess weight, with researchers saying raised insulin levels and inflammation may play a part.
The findings come from researchers at the Institute of Cancer Research, London and Imperial College London, who analysed national cancer registry data for England from 2001 to 2019.
In England, around 31,000 cancers were diagnosed in people aged 20 to 49 in 2023, equal to roughly one in every 1,000 people. This compares with 244,000 cases in the 50 to 79 age group, where the rate is around one in 100.
Concerns have been growing in recent years over rising rates of cancers such as bowel and ovarian in younger adults.
Among the younger group, breast cancer was the most common, with 8,500 cases, followed by bowel cancer at 3,000 and melanoma skin cancer with 2,800 diagnoses.
For nine of the 11 cancers identified, rates are rising in younger adults but also increasing in older adults, who are much more likely to develop the disease. Bowel and ovarian cancer were the exceptions, rising only in younger age groups.
The researchers found that bowel cancer rates in younger women linked to BMI rose faster, from 0.9 to 1.6 per 100,000 people, than those not linked to BMI, which rose from 6.4 to 9.6 per 100,000 people. Similar patterns were recorded for men.
However, the authors noted that the overall number of cases of BMI-linked bowel cancer in younger women remained lower than those not linked to BMI, suggesting other factors must be contributing to the increase.
Several suspected contributors, including ultra-processed foods, antibiotic use and air pollution, have been proposed in recent years. However, many of these factors have also shown stable or declining trends in the UK, the team said.
Despite the rise in several cancer rates among younger adults over the past two decades, most established risk factors, including smoking, alcohol consumption, red or processed meat intake, low fibre diets and lack of exercise, remained stable or even declined in the period leading up to diagnosis.
This suggests these traditional risk factors are unlikely to account for much of the increase in cancer cases.
By contrast, overweight and obesity, which have increased steadily since 1995, could be key factors in the rise in cases. The team suggested that between 2001 and 2019, around 20 per cent of the increase in bowel cancer was explained by increases in BMI over that period.
However, the researchers said rises in BMI alone are not enough to explain the overall increase in cancer among younger adults in England and that there are likely to be other causes.
Data also suggest around 15 per cent of bowel cancer in younger people could be linked to being overweight or obese, with around 40 to 50 per cent in total linked to the combined effect of known risk factors such as obesity, lack of exercise, alcohol and smoking.
Montse García-Closas, professor at the ICR, said more research was needed, but “we cannot wait to act”.
She told a media briefing: “Our main conclusion is that although BMI is our best clue, much of the increase still remains unexplained, and we’ve done some additional analysis that show that most likely what’s missing is not just a single cause unexplained, but it’s likely a combination of multiple factors that act together.”
Amy Berrington, professor at the ICR, said: “Although rates have been increasing, cancer in young people is still a rare disease.”
Marc Gunter, professor at Imperial, said obesity was a known risk factor for around 19 different cancers.
He added: “For some of these cancers, including colorectal (bowel) cancer, we think this could be partly caused by higher levels of hormones such as insulin, which is often elevated in people with obesity, as well as inflammation.
“We know people with obesity have higher levels of insulin, and insulin is a growth factor and has been linked to cancer.
“In a recent study, we actually found that insulin in particular might be playing a role in early onset colorectal (bowel) cancer, and this is actually an area of very active research at the moment.”
The researchers called for large, long-term studies to identify all the biological and environmental factors that could explain rising cancer rates in young adults.
García-Closas added: “Tackling obesity across all ages, particularly in children and young people, through stronger public health policies and wider access to effective interventions, could slow the rise in cancer and prevent many cancers and must become a national priority.”
Michelle Mitchell, Cancer Research UK’s chief executive, said: “Globally, and in the UK, we’re seeing a small increase in cancer rates in adults under 50.
“The picture is complex and we need more research to understand what’s driving the trend, but this study helps to fill in some gaps.
“Overweight and obesity doesn’t explain the rise in full though. Improvements in detection are likely to also be playing a part, meaning that more people are being diagnosed at a younger age.
“Preventing cancer cases must be a priority for the UK government. Smoking remains a leading cause of cancer in adults under 50, which is why the Tobacco and Vapes Bill receiving royal assent this week is such a historic moment.
“Measures to restrict the advertising and promotion of junk food, introducing mandatory reporting and targets on healthy food sales, and making nutritious food more accessible to everyone would all help people keep a healthy weight.”
Diagnosis
WHO launches AI tool for reproductive health information

The World Health Organization (WHO) has launched an AI tool in beta to help policymakers, experts and healthcare professionals access sexual and reproductive health information faster.
Called ChatHRP, the tool was created by WHO’s Human Reproduction Programme and draws only on verified research and guidance collected by HRP and WHO.
It uses natural language processing and retrieval-augmented generation to produce referenced content and cut the time spent searching through documents across different platforms and databases.
WHO said ChatHRP also has multilingual capabilities and low-bandwidth functionality to support use in a wide range of settings.
The beta-testing phase is aimed at a broad professional audience, including policymakers, healthcare workers, researchers and civil society groups.
WHO said the tool can help users quickly access up-to-date evidence, find sources for academic work and verify information on sexual and reproductive health and rights.
Examples of questions it can answer include the latest violence against women data in Oceania for women aged 15 to 49, recommendations on managing diabetes during pregnancy, and whether PrEP and contraception can be used at the same time. PrEP is medicine used to reduce the risk of getting HIV.
WHO added that the system will be updated regularly as new HRP materials are published and includes a feedback loop so users can flag gaps in the information provided.
The launch comes amid wider concern about misinformation in sexual and reproductive health.
A 2025 scoping review found that misinformation in digital spaces is a systemic issue that can undermine human rights, reinforce discriminatory social norms and exclude marginalised voices.
The review also said misinformation can affect health systems by shaping provider knowledge and practice, disrupting service delivery and creating barriers to equitable care.
WHO said ChatHRP is intended to give users streamlined access to reliable information as a counter to “algorithms, opinions, or misinformation”.
Fertility1 week agoFuture Fertility raises Series A financing to scale AI tools redefining fertility care worldwide
Fertility2 weeks agoFuture Fertility partners with Japan’s leading IVF provider, Kato Ladies Clinic
Menopause3 weeks agoMore research needed to understand link between brain fog and menopause, expert says
Mental health2 weeks agoLifting weights shows mental health and cognitive benefits in older women, study finds
News3 weeks agoSelf-employment linked to better cardiovascular health outcomes in Hispanic women
Entrepreneur3 weeks agoFlora Fertility closes US$5m seed round
News4 days agoWomen’s digital health market set to reach US$5.28 billion in 2026 – report
News2 weeks agoResistance training has preventative effects in menopause, study finds















2 Comments